Markets.com Logo

CHRRF

$--
--%
1d
1w
1m

Analysis and statistics

  • Open
    14.4084$
  • Previous Close
    14.4084$
  • 52 Week Change
    4.39$
  • Day Range
    0.00$
  • 52 Week High/Low
    12.5539$ - 16.9479$
  • Dividend Per Share
    0
  • Market cap
    377 M$
  • EPS
    0.8896
  • Beta
    1.947
  • Volume
    --

About

CHRRF.US represents stock in Chrysos Corporation, an Australian company specializing in mineral analysis technology for the mining industry. The symbol is used to denote its over-the-counter (OTC) trading of shares in the United States. The company's primary technology, PhotonAssay, is a faster and more environmentally friendly alternative to traditional fire assay methods for determining gold and other precious metal concentrations in samples.
USD/JPY Forecast: Analyzing the 161.60 Threshold Amid BoJ Policy Friction and Intervention Risks

USD/JPY Forecast: Analyzing the 161.60 Threshold Amid BoJ Policy Friction and Intervention Risks

Julian Parker|--
Crude Oil Price Forecast 2026–2030: Macro Fundamentals, Geopolitics, and Trading Strategies

Crude Oil Price Forecast 2026–2030: Macro Fundamentals, Geopolitics, and Trading Strategies

Julian Parker|--
SpaceX Stock Forecast 2027, 2031 and 2036: What the Lockup Schedule Means for SPCX Shares

SpaceX Stock Forecast 2027, 2031 and 2036: What the Lockup Schedule Means for SPCX Shares

Julian Parker|--
USD/CAD Forecast: Oil Weakness Keeps 1.4000 in Focus

USD/CAD Forecast: Oil Weakness Keeps 1.4000 in Focus

Julian Parker|--
Bitcoin and the Fed’s Guidance Shift: Short-Term Risk, Long-Term Narrative

Bitcoin and the Fed’s Guidance Shift: Short-Term Risk, Long-Term Narrative

Julian Parker|--
Silver Price Forecast: XAG/USD Holds Below $70 as Fed Decision Shapes Outlook

Silver Price Forecast: XAG/USD Holds Below $70 as Fed Decision Shapes Outlook

Julian Parker|--
EUR/USD Outlook: Dollar Firms Before Fed Decision as Euro Rally Loses Momentum

EUR/USD Outlook: Dollar Firms Before Fed Decision as Euro Rally Loses Momentum

Julian Parker|--

Factors

[Company Performance]: Strong revenue growth, profitability, and positive clinical trial results for ChromaDex's Niagen product generally boost investor confidence and drive up the stock price.

[Regulatory Environment]: Favorable decisions from regulatory bodies, such as FDA approvals or positive safety assessments of Niagen, tend to increase demand and positively impact the stock's value.

[Market Sentiment]: Overall market conditions, economic outlook, and investor risk appetite influence the demand for CHRRF.US. Positive market sentiment can lead to increased buying pressure.

[Competition]: The emergence of competing products or increased competition in the NAD+ boosting supplement market could negatively impact ChromaDex's market share and stock price.

[Intellectual Property]: The strength and protection of ChromaDex's patents surrounding Niagen are critical. Any challenges to their IP rights could create uncertainty and lower the stock price.

People Also Watch

Latest news

Kospi's $474 Billion Rout Exposes AI Concentration Risks Ahead of Micron Report

Kospi's $474 Billion Rout Exposes AI Concentration Risks Ahead of Micron Report

Julian Parker|--
Gold Approaches Critical $4,000 Threshold as Hawkish Fed Repricing Eclipses Geopolitical Premium

Gold Approaches Critical $4,000 Threshold as Hawkish Fed Repricing Eclipses Geopolitical Premium

Julian Parker|--
WTI Crude Edges Higher but Remains Under Pressure Near $72.50 After Recent Low

WTI Crude Edges Higher but Remains Under Pressure Near $72.50 After Recent Low

Julian Parker|--

Latest Education Articles

11 Best Swap-Free Account CFD Brokers in Dubai 2026

11 Best Swap-Free Account CFD Brokers in Dubai 2026

Julian Parker|--
11 Best Swap-free Account CFD Brokers in 2026

11 Best Swap-free Account CFD Brokers in 2026

Julian Parker|--
Do You Have to Be Muslim for a Swap-Free Account?

Do You Have to Be Muslim for a Swap-Free Account?

Julian Parker|--
Recommended Topics